Effect of Intravitreal Anti-VEGF on Retinal Vessels Diameter

Sponsor
University of Malaya
Study ID
NCT01626339
Status
Unknown

Conditions

  • Age Related Macular Degeneration

Eligibility Criteria

Sex
ALL
Age
20 Years - 90 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

Patients who will be scheduled for intravitreal injection of Ranibizumab or Bevacizumab will be recruited in this prospective self-controlled trial. Fundus photography will carried out at baseline immediately before injection and at 3, 7 days and 30 days after the first injection. Using image analysis software, measurements summarized as the central retinal artery equivalent (CRAE) and central retinal vein equivalent (CRVE). Null Hypothesis: There is no significant difference between arteriolar/venular diameter before and after injection of intravitreal ranibizumab/bevacizumab in the treated and untreated eye

Key Dates

First listed
Jun 22, 2012
Start date
Apr 30, 2012
Status verified
Jun 2012
Primary completion
Jun 30, 2012

Study Design

Enrollment
30 participants (estimated)

Central Contacts

Related Studies